Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity

被引:32
作者
Zhang, RS
Straus, FH
DeGroot, LJ
机构
[1] Univ Chicago, Thyroid Study Unit, Dept Med, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
关键词
D O I
10.1089/105072501300042749
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A replication defective adenovirus transducing thymidine kinase (TK) gene under the control of the rat thyroglobulin (rTg) promoter (AdrTgtk) was developed to evaluate its cell-specific killing activity in gene therapy. We also developed adenoviruses containing the TK gene driven by the cytomegalovirus (CMV) promoter (Ad-CMVtk), and luciferase (Luc) gene driven by the rTg or CMV promoter (AdrTgLuc or AdCMVLuc). Luc activity in FRTL-5, HepG2 COS1, rMTC, hMTC, Hela, GH3, T98G, and CA77 cells was measured after infection with AdrTgLuc or AdCMVLuc. FRTL-5 cells produce thyroglobulin (Tg), whereas all other cells are non-Tg-producing cell lines. Transduction by AdCMVLuc caused high Luc activity in all cell lines. However, infection with AdrTgLuc induced Luc activity only in FRTL-5 cells. AdCMVtk or AdrTgtk was used to transduce various cell lines to evaluate the different killing effect. After infection with AdCMVtk vector followed by ganciclovir (GCV) treatment, cell growth was strongly suppressed in all cell lines compared both to noninfected cells and to cells infected by AdCMVLuc in the presence of GCV. When FRTL-5 cells were infected with AdrTgtk followed by GCV treatment, more than 90% were killed, but only a minimal effect was observed in other cell lines, indicating that the Tg promoter transduced TK expression only in Tg-producing cells. When adenovirus is given intravenously, liver and spleen are the major organs infected. A high Luc activity was found in liver and spleen of AdCMVLuc treated animals. No Luc activity was found in liver and spleen of AdrTgLuc-treated animals, indicating that rTg does not transduce Luc expression in non-Tg-producing tissues in. vivo. No significant changes of the serum transaminase levels and histologic abnormalities were found in animals treated with AdrTgtk/GCV compared with control animals. High levels of serum transaminases, lymphocyte infiltration, some Kupffer's cell prominence, and extensive single cell hypatocyte death were found in AdCMVtk/GCV-treated animals, indicating severe liver damage induced, as expected, by a noncell-specific promoter. These results indicate that transfer of TK gene driven by the rTg promoter has thyroid cell-specific killing ability in the presence of GCV, little in vivo toxicity, and should be useful in the future for treating thyroid Tg-producing cancers.
引用
收藏
页码:115 / 123
页数:11
相关论文
共 70 条
[1]   CULTURE OF HORMONE-DEPENDENT FUNCTIONAL EPITHELIAL-CELLS FROM RAT THYROIDS [J].
AMBESIIMPIOMBATO, FS ;
PARKS, LAM ;
COON, HG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (06) :3455-3459
[2]   Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer [J].
Anderson, LM ;
Swaminathan, S ;
Zackon, I ;
Tajuddin, AK ;
Thimmapaya, B ;
Weitzman, SA .
GENE THERAPY, 1999, 6 (05) :854-864
[3]   IN-SITU DELIVERY OF SUICIDE GENES FOR CANCER-TREATMENT [J].
BLAESE, RM ;
ISHIIMORITA, H ;
MULLEN, C ;
RAMSEY, J ;
RAM, Z ;
OLDFIELD, E ;
CULVER, K .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (08) :1190-1193
[4]   Retrovirus-mediated suicide gene prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter [J].
Braiden, V ;
Nagayama, Y ;
Iitaka, M ;
Namba, H ;
Niwa, M ;
Yamashita, S .
ENDOCRINOLOGY, 1998, 139 (09) :3996-3999
[5]   Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12 [J].
Bramson, JL ;
Hitt, M ;
Addison, CL ;
Muller, WJ ;
Gauldie, J ;
Graham, FL .
HUMAN GENE THERAPY, 1996, 7 (16) :1995-2002
[6]  
CANHEUVERSUYN B, 1985, FEBS LETT, V188, P192
[7]   Gene therapy strategies for the treatment of pituitary tumours [J].
Castro, MG .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 1999, 22 (01) :9-18
[8]   Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter [J].
Chen, L ;
Chen, DS ;
Manome, Y ;
Dong, YH ;
Fine, HA ;
Kufe, DW .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (06) :2775-2782
[9]   IDENTIFICATION OF A CAMP-RESPONSIVE REGION IN THYROGLOBULIN GENE PROMOTER [J].
CHRISTOPHE, D ;
GERARD, C ;
JUVENAL, G ;
BACOLLA, A ;
TEUGELS, E ;
LEDENT, C ;
CHRISTOPHEHOBERTUS, C ;
DUMONT, JE ;
VASSART, G .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1989, 64 (01) :5-18
[10]   Expression of a transactivation-deficient form of thyroid transcription factor I decreases the activity of co-transfected thyroglobulin and thyroperoxidase promoters [J].
ChristopheHobertus, C ;
vanRenterghem, P ;
Pichon, B ;
Christophe, D .
FEBS LETTERS, 1996, 399 (1-2) :140-142